Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294.
Gale DD, Hofer P, Spina D, Seeds EA, Banner KH, Harrison S, Douglas G, Matsumoto T, Page CP, Wong RH, Jordan S, Smith F, Banik N, Halushka PV, Cavalla D, Rotshteyn Y, Kyle DJ, Burch RM, Chasin M. Gale DD, et al. Among authors: burch rm. Pulm Pharmacol Ther. 2003;16(2):97-104. doi: 10.1016/S1094-5539(02)00175-X. Pulm Pharmacol Ther. 2003. PMID: 12670778 Review.
Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers.
Gale DD, Landells LJ, Spina D, Miller AJ, Smith K, Nichols T, Rotshteyn Y, Tonelli A, Lacouture P, Burch RM, Page CP, O'Connor BJ. Gale DD, et al. Among authors: burch rm. Br J Clin Pharmacol. 2002 Nov;54(5):478-84. doi: 10.1046/j.1365-2125.2002.01682.x. Br J Clin Pharmacol. 2002. PMID: 12445026 Free PMC article. Clinical Trial.
Thiocarbazate building blocks enable the construction of azapeptides for rapid development of therapeutic candidates.
Altiti A, He M, VanPatten S, Cheng KF, Ahmed U, Chiu PY, Mughrabi IT, Jabari BA, Burch RM, Manogue KR, Tracey KJ, Diamond B, Metz CN, Yang H, Hudson LK, Zanos S, Son M, Sherry B, Coleman TR, Al-Abed Y. Altiti A, et al. Among authors: burch rm. Nat Commun. 2022 Nov 28;13(1):7127. doi: 10.1038/s41467-022-34712-9. Nat Commun. 2022. PMID: 36443291 Free PMC article.
Effects of Rapastinel (Formerly GLYX-13) on Serum Brain-Derived Neurotrophic Factor in Obsessive-Compulsive Disorder.
Linkovski O, Shen H, Zwerling J, Filippou-Frye M, Jo B, Cordell E, Cooper TB, Simpson HB, Burch RM, Moskal JR, Lee F, Rodriguez CI. Linkovski O, et al. Among authors: burch rm. J Clin Psychiatry. 2018 Jan/Feb;79(1):17l11824. doi: 10.4088/JCP.17l11824. J Clin Psychiatry. 2018. PMID: 29505186 Free PMC article. Clinical Trial. No abstract available.
The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus.
Burgdorf J, Zhang XL, Weiss C, Gross A, Boikess SR, Kroes RA, Khan MA, Burch RM, Rex CS, Disterhoft JF, Stanton PK, Moskal JR. Burgdorf J, et al. Among authors: burch rm. Neuroscience. 2015 Nov 12;308:202-11. doi: 10.1016/j.neuroscience.2015.09.004. Epub 2015 Sep 4. Neuroscience. 2015. PMID: 26343295 Free PMC article.
Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats.
Burgdorf J, Kroes RA, Zhang XL, Gross AL, Schmidt M, Weiss C, Disterhoft JF, Burch RM, Stanton PK, Moskal JR. Burgdorf J, et al. Among authors: burch rm. Behav Brain Res. 2015 Nov 1;294:177-85. doi: 10.1016/j.bbr.2015.07.039. Epub 2015 Jul 22. Behav Brain Res. 2015. PMID: 26210936 Free PMC article.
Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM; GLYX-13 Clinical Study Group. Preskorn S, et al. Among authors: burch rm. J Psychiatr Pract. 2015 Mar;21(2):140-9. doi: 10.1097/01.pra.0000462606.17725.93. J Psychiatr Pract. 2015. PMID: 25782764 Clinical Trial.
102 results